SI2256108T1 - Substituirani triazinski kinazni inhibitorji - Google Patents

Substituirani triazinski kinazni inhibitorji

Info

Publication number
SI2256108T1
SI2256108T1 SI200332475A SI200332475A SI2256108T1 SI 2256108 T1 SI2256108 T1 SI 2256108T1 SI 200332475 A SI200332475 A SI 200332475A SI 200332475 A SI200332475 A SI 200332475A SI 2256108 T1 SI2256108 T1 SI 2256108T1
Authority
SI
Slovenia
Prior art keywords
kinase inhibitors
substituted triazine
triazine kinase
substituted
inhibitors
Prior art date
Application number
SI200332475A
Other languages
English (en)
Inventor
Gee-Hong Kuo
Alan Deangelis
Aihua Wang
Yan Zhang
Stuart L Emanuel
Steve A Middleton
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SI2256108T1 publication Critical patent/SI2256108T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200332475A 2002-07-18 2003-07-18 Substituirani triazinski kinazni inhibitorji SI2256108T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39694802P 2002-07-18 2002-07-18
EP10176670.7A EP2256108B1 (en) 2002-07-18 2003-07-18 Substituted triazine kinase inhibitors

Publications (1)

Publication Number Publication Date
SI2256108T1 true SI2256108T1 (sl) 2016-05-31

Family

ID=30770960

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332475A SI2256108T1 (sl) 2002-07-18 2003-07-18 Substituirani triazinski kinazni inhibitorji

Country Status (9)

Country Link
US (1) US7205298B2 (sl)
EP (2) EP2256108B1 (sl)
AU (1) AU2003259153A1 (sl)
CY (1) CY1117951T1 (sl)
DK (1) DK2256108T3 (sl)
ES (2) ES2392426T3 (sl)
HU (1) HUE029020T2 (sl)
SI (1) SI2256108T1 (sl)
WO (1) WO2004009562A1 (sl)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307268D0 (en) * 2003-03-28 2003-05-07 Syngenta Ltd Organic compounds
WO2005033095A1 (en) * 2003-10-03 2005-04-14 Dow Agrosciences Llc Fungicidal 4-(2-aminopyridin-4-yl)-n-phenyl-1,3,5-triazin-2-amine derivatives
JP4936897B2 (ja) 2003-12-18 2012-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗増殖剤としてのピリド−およびピリミドピリミジン誘導体
UA84930C2 (ru) 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
NZ564179A (en) 2005-06-30 2010-09-30 Janssen Pharmaceutica Nv Cyclic anilino - pyridinotriazines as GSK-3 inhibitors
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2654583C (en) 2006-07-13 2015-11-24 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2693715C (en) 2007-07-27 2015-10-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010105243A1 (en) 2009-03-13 2010-09-16 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US20130023497A1 (en) * 2009-06-08 2013-01-24 Chunlin Tao Triazine Derivatives and their Therapeutical Applications
US8785450B2 (en) 2009-06-29 2014-07-22 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
EP2484683A4 (en) 2009-09-02 2014-09-03 Lg Chemical Ltd ORGANOTINE COMPOUND, PROCESS FOR THE PREPARATION THEREOF AND METHOD FOR THE PRODUCTION OF POLYMILIC ACID THEREWITH
EP3561077B1 (en) 2009-10-21 2022-12-21 Les Laboratoires Servier Methods for cell-proliferation-related disorders
RS54544B1 (en) 2010-09-13 2016-06-30 Novartis Ag TRIAZINE-OXADIAZOLES
EA201390717A1 (ru) * 2010-11-17 2013-10-30 Новартис Аг 3-(аминоарил)пиридиновые соединения
CN103339110A (zh) * 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
WO2012117048A1 (en) * 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
US9242937B2 (en) 2011-03-02 2016-01-26 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted pyridine derivatives
MX2013012233A (es) 2011-04-19 2014-01-23 Bayer Pharma AG 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
PL3406251T3 (pl) 2011-05-03 2024-04-29 Agios Pharmaceuticals, Inc. Aktywatory kinazy pirogronianowej do stosowania w terapii
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
AU2012262489A1 (en) 2011-05-27 2013-04-04 Icahn School Of Medicine At Mount Sinai Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013033657A2 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY
EP2755948B1 (en) 2011-09-16 2016-05-25 Bayer Intellectual Property GmbH Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
CA2848616A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
EP2785721A1 (en) 2011-11-30 2014-10-08 Actelion Pharmaceuticals Ltd. 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
SI2800743T1 (sl) 2012-01-06 2018-08-31 Agios Pharmaceuticals, Inc. Terapevtsko aktivne spojine in načini njihove uporabe
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CA2888381A1 (en) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
CN104854091B (zh) 2012-10-18 2018-04-03 拜耳药业股份公司 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
TW201429972A (zh) 2013-01-09 2014-08-01 Actelion Pharmaceuticals Ltd 抗菌噁唑酮衍生物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3019480B1 (en) 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
MY185687A (en) * 2013-07-11 2021-05-30 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EA030428B1 (ru) 2013-08-02 2018-08-31 Аджиос Фармасьютикалз, Инк. Терапевтически активные соединения и способы их применения
US20160221991A1 (en) * 2013-09-20 2016-08-04 Carna Biosciences, Inc. Novel triazine derivative
KR102400737B1 (ko) 2014-03-14 2022-05-20 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
CN107207475A (zh) 2014-10-16 2017-09-26 拜耳医药股份有限公司 含有砜基团的氟化苯并呋喃基‑嘧啶衍生物
CN107427520A (zh) 2015-03-24 2017-12-01 拜耳医药股份有限公司 4‑(4‑氟‑2‑甲氧基苯基)‑n‑{3‑[(s‑甲基磺酰亚氨基)甲基]苯基}‑1,3,5‑三嗪‑2‑胺用于治疗淋巴瘤的用途
CA2980493A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma
WO2016150902A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
WO2016201227A1 (en) 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
AU2016303614A1 (en) 2015-08-05 2018-02-15 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
CN108290903B (zh) 2015-09-29 2021-09-03 拜耳医药股份有限公司 新的大环磺酰二亚胺化合物
EP3359544B1 (en) 2015-10-08 2020-08-12 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
EP4403173A3 (en) 2015-10-15 2024-10-09 Les Laboratoires Servier Combination therapy for treating malignancies
EP3601253B1 (en) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
BR112020016389A2 (pt) 2018-02-13 2020-12-15 Bayer Aktiengesellschaft Uso de 5-fluor-4-(4-fluor-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para tratamento de linfoma difuso de células b grandes
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN109503473B (zh) * 2019-01-07 2020-07-07 上海慧川生物医药科技有限公司 2-甲氧基-3-氨基-5-吡啶硼酸频哪醇酯及其中间体的合成方法
CN110357863B (zh) * 2019-08-27 2023-04-14 药雅科技(上海)有限公司 一种三嗪双芳香环衍生物表皮生长因子抑制剂及其制备方法与用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332948T2 (de) 1992-03-05 2003-11-27 Board Of Regents, The University Of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5902795A (en) 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
CA2216943C (en) 1995-04-19 2003-06-17 Schneider (Usa) Inc. Drug release coated stent
US6342221B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
JP3499808B2 (ja) 2000-06-29 2004-02-23 本田技研工業株式会社 電子文書分類システム

Also Published As

Publication number Publication date
ES2392426T3 (es) 2012-12-10
US7205298B2 (en) 2007-04-17
HUE029020T2 (en) 2017-02-28
ES2575522T3 (es) 2016-06-29
US20040082581A1 (en) 2004-04-29
EP1546121B1 (en) 2012-08-29
EP2256108A1 (en) 2010-12-01
CY1117951T1 (el) 2017-05-17
EP1546121A1 (en) 2005-06-29
AU2003259153A1 (en) 2004-02-09
DK2256108T3 (en) 2016-04-11
EP2256108B1 (en) 2016-03-23
EP1546121A4 (en) 2007-08-15
WO2004009562A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
SI2256108T1 (sl) Substituirani triazinski kinazni inhibitorji
PL373649A1 (en) Kinase inhibitors
SI1569907T1 (sl) Na nikotinamidu osnovani kinazni inhibitorji
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
AU2003299651A8 (en) Tyrosine kinase inhibitors
EP1558609A4 (en) KINASE INHIBITORS
EP1543009A4 (en) Pyrrolotriazine KINASE INHIBITORS
EP1539763A4 (en) Azaindole KINASE INHIBITORS
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
AU2003249442A1 (en) Kinase inhibitors
AU2003298942A8 (en) Tyrosine kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
AP2006003620A0 (en) Imidazopyrazine tyroshine kinase inhibitors
AU2003282891A8 (en) Novel tyrosine kinases inhibitors
EP1497019A4 (en) USE AS KINASEINHIBITORS USEFUL PYRROLO-TRIAZIN-ANILINE COMPOUNDS
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
EP1534268A4 (en) TYROSINE KINASE INHIBITORS
EP1581539A4 (en) NEW TYROSINE KINASE HEMMER
HK1071758A1 (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
AU2003275282A8 (en) Novel tyrosine kinase inhibitors
AU2003237446A1 (en) Pyrazole-derivatives as p38 kinase inhibitors
AU2003254051A8 (en) Pyrazolopyrimidines as kinase inhibitors
PL378116A1 (pl) Heterocykliczne inhibitory kinazy